Skip to content

Clinical study on the predictive effect of liver reserve function test combined with end-stage liver disease model score on the prognosis of patients with hepatitis B associated chronic acute liver failure

Clinical study on the predictive effect of liver reserve function test combined with end-stage liver disease model score on the prognosis of patients with hepatitis B associated chronic acute liver failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079944
Enrollment
Unknown
Registered
2024-01-17
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHB, acute-on-chronic liver failure

Interventions

This study is a prospective observational study and does not involve different interventions groups or clinical features
:All patients received routine clinical treatment and completed liver reserve function testing. Liver reserve function testing is also a mature and commonly used liver function testing method in clini

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age range from 18 to 75 years old, regardless of gender; (2) The diagnostic criteria of HBV-ACLF refer to the Guidelines for the Diagnosis and Treatment of Liver Failure (2018 version), and the diagnostic criteria of chronic viral hepatitis B refer to the Guidelines for the Diagnosis and Treatment of Chronic Hepatitis B (2022 version): on the basis of chronic hepatitis B virus infection, acute or subacute clinical symptoms of decompensation of liver function occur in a short period of time, which are manifested as: ? extreme fatigue with obvious gastrointestinal symptoms; ? Jaundice rapidly deepens, with serum total bilirubin exceeding the upper limit of normal by 10 times or daily increase of = 17.1 µ Mol/L; ? Bleeding tendency, PTA = 40% (or INR = 1.5), and excluding other causes; ? Decompensated ascites; ? Accompanied or not accompanied by hepatic encephalopathy.

Exclusion criteria

Exclusion criteria: Concomitant hepatitis A, hepatitis C, hepatitis D, and hepatitis E, combined with CMV and EBV infections, combined with hyperthyroidism and autoimmune diseases, combined with severe heart, lung, and kidney dysfunction or malignant tumors, combined with HIV infection, combined with pregnancy, previous history of heavy alcohol consumption, recent history of using anti tuberculosis drugs, recent intake of traditional Chinese medicine, weight loss drugs, and various health products.

Design outcomes

Primary

MeasureTime frame
Survival outcome;

Secondary

MeasureTime frame
Number of readmissions;

Countries

China

Contacts

Public ContactZHU XIA

West China Hospital of Sichuan University

26508292@qq.com+86 139 8002 4909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026